| abstract |
A method of predicting the sensitivity of tumor cell growth to an AKT inhibitor, comprising determining the presence of an AKT mutation, wherein the presence of an AKT mutation correlates with the sensitivity of the cell to the inhibitor of AKT, where the AKT inhibitor is (S) -2- (4-chlorophenyl) -1- (4 - ((5R, 7R) -7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta [d] pyrimidin-4-yl) piperazin-1-yl) -3- (isopropylamino) propan-1-one, or a pharmaceutically acceptable salt thereof, wherein the mutation corresponds to, or is aligned with, L52, K189 or D323. |